Primary Biliary Cholangitis
72
15
22
26
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
15 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
8 terminated out of 72 trials
76.5%
-10.1% vs benchmark
28%
20 trials in Phase 3/4
58%
15 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 26 completed trials
Clinical Trials (72)
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
LEOPARD Prospective Validation Cohort 1
LEOPARD Training and Validation Data Collection Study
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate